S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: A randomised, multicentre, open-label, phase 2 trial

The Lancet Oncology

Volumn 17, Issue 1, 2016, Pages 99-108

  Hironaka, Shuichi ^a   Sugimoto, Naotoshi ^b   Yamaguchi, Kensei ^c   Moriwaki, Toshikazu ^d   Komatsu, Yoshito ^e   Nishina, Tomohiro ^f   Tsuji, Akihito ^g   Nakajima, Takako Eguchi ^h   Gotoh, Masahiro ⁱ   Machida, Nozomu ^j   Bando, Hideaki ^k   Esaki, Taito ^l   Emi, Yasunori ^m   Sekikawa, Takashi ⁿ   Matsumoto, Shigemi ^o   Takeuchi, Masahiro ^p   Boku, Narikazu ^h   Baba, Hideo ^q   Hyodo, Ichinosuke ^d  

^a CHIBA CANCER CENTER   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c Saitama Cancer Centre   (Japan)

^d UNIVERSITY OF TSUKUBA   (Japan)

^e HOKKAIDO UNIVERSITY   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^g KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^h ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ OSAKA MEDICAL COLLEGE HOSPITAL   (Japan)

^j SHIZUOKA CANCER CENTER   (Japan)

^k NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^l NATIONAL HOSPITAL ORGANIZATION   (Japan)

^m SAISEIKAI FUKUOKA GENERAL HOSPITAL   (Japan)

ⁿ SHOWA UNIVERSITY NORTHERN YOKOHAMA HOSPITAL   (Japan)

^o KYOTO UNIVERSITY HOSPITAL   (Japan)

^p KITASATO UNIVERSITY   (Japan)

^q KUMAMOTO UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DRUG COMBINATION; FOLINIC ACID; OTERACIL; OXALIPLATIN; PLATINUM COMPLEX; S 1 (COMBINATION); TEGAFUR;

ADENOCARCINOMA; AGED; ANEMIA; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG COMBINATION; EATING DISORDER; FEMALE; HUMAN; HYPONATREMIA; MALE; MIDDLE AGED; MULTICENTER STUDY; NEUTROPENIA; PATHOLOGY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADENOCARCINOMA; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEEDING AND EATING DISORDERS; FEMALE; HUMANS; HYPONATREMIA; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS; OXONIC ACID; STOMACH NEOPLASMS; SURVIVAL RATE; TEGAFUR; TREATMENT OUTCOME;

EID: 84955398652     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00410-6     Document Type: Article

References (20)

1. GLOBOCAN 2012: cancer incidence and mortality worldwide International Agency for Research on Cancer, (accessed Aug 14, 2015). http://globocan.iarc.fr/Default.aspx.
2. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008, 9:215-221.
3. Yamada Y, Higuchi K, Nishikawa K, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol 2015, 26:141-148.
4. Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009, 20:666-673.
5. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008, 358:36-46.
6. Boku N, Yamamoto S, Fukuda H, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009, 10:1063-1069.
7. Thirion P, Michiels S, Pignon JP, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004, 22:3766-3775.
8. Douillard JY, Hoff PM, Skillings JR, et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002, 20:3605-3616.
9. Carmichael J, Popiela T, Radstone D, et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002, 20:3617-3627.
10. Van Cutsem E, Findlay M, Osterwalder B, et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 2000, 18:1337-1345.
11. Koizumi W, Boku N, Yamaguchi K, et al. Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer. Ann Oncol 2010, 21:766-771.
12. Denda T, Li J, Xu R, et al. Phase II study of S-1 plus leucovorin (a new 1-week treatment regimen followed by a 1-week rest period) in patients with untreated metastatic colorectal cancer in Japan and China. Proc Am Soc Clin Oncol 2012, 30(suppl 4). abstr 2012.
13. Yamazaki K, Kuwano H, Ojima H, et al. A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer. Cancer Chemother Pharmacol 2015, 75:569-577.
14. Hyodo I, Nishina T, Boku N, et al. Phase I study of oral fluoropyrimidine S-1 plus oral leucovorin in patients with metastatic colorectal cancer. Ann Oncol 2006, 17(suppl 9). abstr 2006.
15. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
16. Pocock SJ, Simon R Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975, 31:103-115.
17. Simon R, Wittes RE, Ellenberg SS Randomized phase II clinical trials. Cancer Treat Rep 1985, 69:1375-1381.
18. Narahara H, Iishi H, Imamura H, et al. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer 2011, 14:72-80.
19. Koizumi W, Kim YH, Fujii M, et al. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol 2014, 140:319-328.
20. Okusaka T, Ueno M, Omuro Y, et al. A randomized phase II study of S-1 plus leucovorin versus S-1 alone in patients with gemcitabine-refractory pancreatic cancer. ESMO 2013, (suppl 34). abstr 406.